Search “anti-aging peptides” and you will find hundreds of pages promising younger cells, longer telomeres and reversed aging. Almost none of them tell you how far the science has actually gotten. This post sorts the compounds people ask about most by what has really been shown, and in whom. The short version: no peptide has been shown to slow aging in humans. Some are interesting, one now has an FDA approval for a rare disease, and most are still in cells and mice.

Why peptides draw so much longevity interest
Aging research has converged on a few “hallmarks”: declining mitochondrial function, accumulation of senescent cells, shortening telomeres, and loss of structural proteins like collagen. Peptides are short chains of amino acids that can act as signals, so it is natural to ask whether specific ones can nudge those processes. Several candidates map neatly onto individual hallmarks. That tidy story is exactly why it is easy to oversell. A compound that does something in a dish or a mouse often fails in people, and aging itself is not an approved clinical endpoint, which makes human trials slow and hard to design.
SS-31 (elamipretide): the most advanced candidate
SS-31, now called elamipretide, is a small peptide that targets mitochondria and binds cardiolipin, a lipid that helps hold the inner mitochondrial membrane together. It is the only peptide on this list with a real late-stage clinical record. On September 19, 2025, the FDA granted accelerated approval to elamipretide (brand name Forzinity) for Barth syndrome, an ultra-rare mitochondrial disease affecting roughly 150 people in the United States. Approval rested on improved knee muscle strength in the TAZPOWER trial, and the manufacturer must run a confirmatory trial. The labeled use is a daily injection, with injection-site reactions the most common side effect.
What this does not mean is that elamipretide treats aging. In aged mice, researchers have reported improved mitochondrial function in muscle, including a 2023 study on ADP sensitivity in aged mitochondria. That is animal data. Trials in other mitochondrial conditions have had mixed results, and nothing has established an anti-aging benefit in healthy people.
MOTS-c and humanin: mitochondria-derived signals
Most proteins are encoded in the nucleus, but mitochondria carry a little DNA of their own, and a few short peptides come from it. MOTS-c is one. In a 2021 Nature Communications paper from a USC group, MOTS-c levels rose with exercise in a small group of young men (ten volunteers), and treating older mice improved their physical capacity and healthspan measures. That is a fascinating signal, and it is also nearly the whole story: the human part measured natural levels and did not test MOTS-c as a treatment, and most of the work comes from one research network.
Humanin, another mitochondria-derived peptide, has been studied in cells and animals for effects on metabolism and neuroprotection. As far as I could find, there are no completed interventional human trials. Both compounds belong firmly in the “promising biology, unproven medicine” category.
Epitalon: big claims, narrow evidence
Epitalon is a four-amino-acid peptide developed from work on the pineal gland by Vladimir Khavinson and colleagues in Russia. The headline claim is that it activates telomerase, the enzyme that extends telomeres. Telomerase activation has been reported in human cell cultures, and some mouse experiments reported lifespan effects. In one reported mouse experiment, maximum lifespan rose while average lifespan did not. Human data are limited to small studies, many published in Russian-language journals, and the bulk of the literature comes from a single research group.
Two cautions apply. First, I did not find a placebo-controlled human trial that measured telomere length before and after treatment. Second, telomerase is also active in many cancers, which is why activating it is a theoretical concern that careful trials would need to address. Dedicated human safety and dosing studies are not available.
GHK-Cu: real human data, but mostly on skin
GHK-Cu is a copper-binding tripeptide that occurs naturally in plasma and declines with age. It has the most human evidence of any compound here, but nearly all of it is for topical use: creams and serums studied for skin thickness, collagen and wrinkle appearance, often in small trials. Those results do not carry over to injections, which have little controlled human data behind them. If your interest is skin, topical GHK-Cu is where the evidence sits. If someone is selling it as a whole-body longevity injection, the evidence is not there yet.
FOXO4-DRI: a senolytic that stayed in the lab
Senescent cells stop dividing but linger and secrete inflammatory signals. FOXO4-DRI is an engineered peptide designed to disrupt the interaction that keeps those cells alive. In a widely cited 2017 paper in Cell, it cleared senescent cells and improved fitness and kidney function in fast-aging and naturally aged mice. Follow-up work has stayed in cells and animals. There are no human clinical trials, and it is not an approved drug. Online reports of how people feel after taking it are anecdotal and cannot show whether it works or is safe.
What about the regulatory chatter?
You may see claims that regulators are about to open the door to compounding certain peptides. I could not verify any of these against FDA records, and several come from sellers with a stake in the outcome. Even if a compounding committee made a recommendation, that is not an approval, and it would not show that a compound works. Check FDA meeting materials directly before relying on any such claim.
How to read the next headline
- Check the species. “Extends lifespan” almost always means mice or worms. Mouse results fail to translate to people more often than they succeed.
- Check the endpoint. Improved biomarkers, telomere length or cell culture readouts are not the same as living longer or staying healthier.
- Check the source. Many “ranked by evidence” lists are written by companies that sell the compounds. Look for the original paper.
- Check who ran it. Findings repeated by independent groups carry far more weight than a single lab’s results.
- Check the route. Topical, oral and injected versions behave differently. Evidence for one says little about another.
Safety and sourcing: the part ads skip
Even when the biology is plausible, practical risks matter. Peptides sold online as “research chemicals” are not made under the same quality controls as approved drugs, so identity, purity and dose can differ from the label. Injectable products also carry infection risks when contaminated, and long-term safety data simply do not exist for most of these compounds. Elamipretide is the exception only in the narrow sense that it went through formal review for one disease, with a specific dose and monitoring.
There is also the question of who is likely to benefit. A treatment tested in a rare disease, or in old mice with a specific defect, may do little in a healthy adult. And because aging is slow, a short trial can show a biomarker shift without telling us anything about outcomes that matter, such as strength, cognition or disease risk. This is why the gap between “interesting mechanism” and “useful therapy” is usually measured in years.
Where this leaves us
If you rank these by evidence, the order is roughly: elamipretide (approved for a rare disease, not aging), GHK-Cu (topical skin data), then MOTS-c, epitalon, humanin and FOXO4-DRI, which are still at the preclinical or very early stage. The most useful thing the field can produce next is boring: randomized, placebo-controlled human trials with clear endpoints and independent replication. Until then, “anti-aging peptide” describes a research direction, not a proven treatment.
For related reading on this site, see our posts on NAD+ and what the latest research shows and kisspeptin and what human studies show, or bring your questions to the forum.
This article is for educational and research purposes only and is not medical advice. Most compounds discussed here are not approved for anti-aging use. Talk to a qualified clinician before using any peptide.



Leave a Reply